Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Organisation › Details

RhoVac (Group)

RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac’s first drug candidate has completed clinical phase I/II and clinical phase IIb development has been initiated. RhoVac has its headquarters at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. *

 

Period Start 2007-01-01 established
Products Industry BIOTECH
  Industry 2 cancer immunotherapy (immuno-oncology, I-O)
Persons Person Månsson, Anders (Lidds 202209– CEO before RhoVac + Amniotics + LEO Pharma + Ferring Pharmaceuticals)
  Person 2 Stage, Henrik (Adcendo 202107– CFO before CEO formerly Santaris Pharma 201401 CFO)
     
Region Region Lund
  Country Sweden
  Street 1 Scheeletorget
Medicon Village
  City 22381 Lund
  Tel +46-73-751-7278
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: RhoVac AB. (9/2/19). "Press Release: RhoVac Optimizes the Structure of the Management Team and Appoints Anders Månsson as New CEO".
     
   
Record changed: 2024-02-12

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for RhoVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top